Novo Nordisk A/S (ETR:NOV)
Germany
· Delayed Price · Currency is EUR | Market Cap | 194.07B |
| Revenue (ttm) | 41.82B |
| Net Income (ttm) | 14.89B |
| Shares Out | n/a |
| EPS (ttm) | 3.35 |
| PE Ratio | 13.03 |
| Forward PE | 12.16 |
| Dividend | 1.53 (3.51%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 279,028 |
| Average Volume | 820,293 |
| Open | 43.75 |
| Previous Close | 43.79 |
| Day's Range | 43.29 - 44.57 |
| 52-Week Range | 38.51 - 126.34 |
| Beta | 0.27 |
| RSI | 37.39 |
| Earnings Date | Aug 6, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH
Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-ass...
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supple...
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/...
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
On Thursday, Eli Lilly and Co. LLY said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
BENSALEM, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded ...
Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes
The pricing of weight-loss drugs like Lilly's Zepbound and Novo's Wegovy is a pressure point for investors.
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired se...
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The ...
My Favorite 10 Real-Money Blue-Chip Bargains To Buy In August
Yield, growth, and valuation are the core drivers of long-term returns. Safety and quality protect against catastrophic losses and dividend cuts. Dividend growth stocks have outperformed over 50 years...
Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/S
SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (NYSE: NVO) secu...
Investors in Novo Nordisk A/S Should Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights – NVO
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded ...
It's Time To Be All-In On Novo Nordisk
Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempi...
NVO LAWSUIT ALERT: The Gross Law Firm Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class perio...
Novo Nordisk launches weight-loss drug Wegovy in South Africa
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the coun...
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 20...
Former Goldman Sachs, JPMorgan exec gambled away investor funds for his online casino company: feds
Richard Kim was indicted on securities and wire fraud charges related to alleged misappropriation of about $4 million in investor funds for his start-up online casino company, Zero Edge. Kim, who prev...
New York Sues Zelle, Alleging Failure to Prevent Fraud
Zelle operator Early Warning Services is being sued by New York State Attorney General Letitia James, who alleged that the company fails to protect its users from “massive amounts of fraud.” The Offic...
A Cure For Novo Nordisk
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47...
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa., Aug. 13, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit agai...
New York AG James sues Zelle parent company for alleged fraud
New York Attorney General Letitia James sued the parent company of payment network Zelle for allegedly enabling fraud. James alleged that the company knew about ongoing fraud between 2017 and 2023 and...
Novo Nordisk: The Falling Knife That Keeps Giving
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in ob...
New York sues Zelle, says security lapses led to 'rampant' consumer fraud
Zelle was sued on Wednesday by New York Attorney General Letitia James, who said the electronic payment platform's refusal to adopt critical safety features enabled fraudsters to steal more than $1 bi...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors ar...